Because rosacea is an inflammatory disease there is scientific rationale for a possible association between it and other inflammatory diseases. A recent study demonstrates that rosacea patients have a greater percentage of gastrointestinal disorders than do controls and should be evaluated further if they present with GI symptoms. In such cases a systematic approach to the treatment of both conditions may be warranted.
A revised and updated set of criteria and treatment recommendations establishes a phenotype approach to diagnosing and classifying rosacea. This approach marks a transition from treating rosacea patients according to subtype. Global representation may identify research needed to determine whether rosacea is a global condition.
Newer topical agents for rosacea including ivermectin and brimonidine are effective, and soon could be joined by oxymetazoline cream, experts say. Initial results from phase 2 trials of minocycline foam in rosacea could be available by year's end.
Neuroinflammation has recently been recognized as one of the possible factors leading to the development of rosacea. As such, future therapies targeting this pathway could prove effective in rosacea treatment.
Microbial colonization in the development of inflammatory conditions and immune-mediated conditions is a hot research topic, and new dermatologic therapies can potentially result from greater understanding of the role of microbial communities on the skin and in the gut.